The important roles of miR-205 in normal physiology, cancers and as a potential therapeutic target

Current Cancer Drug Targets

Volumn 14, Issue 7, 2014, Pages 621-637

  Vosgha, Haleh ^a   Salajegheh, Ali ^a   Smith, Robert Anthony ^a   Lam, Alfred King Yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer; Carcinoma; microRNA; miRNA 205; Oncogene; Tumour suppressor gene

Indexed keywords

MICRORNA 205; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MICRORNA; MIRN205 MICRORNA, HUMAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DERMATOFIBROSARCOMA PROTUBERANS; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; ESOPHAGUS CANCER; FEMALE GENITAL TRACT CANCER; GENE TARGETING; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; METASTASIS; NEOPLASM; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CARCINOGENESIS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84911469403     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800961407140926105634     Document Type: Article

References (149)

1. Costa, P. M.; Pedroso de Lima, M. C. MicroRNAs as molecular targets for cancer therapy: on the modulation of microRNA expression. Pharmaceuticals (Basel)., 2013, 6, 1195-1220.
2. Pritchard, C. C.; Cheng, H. H.; Tewari M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet., 2012, 13, 358-369.
3. Griffiths-Jones, S.; Saini, H. K.; van Dongen, S.; Enright, A. J. miRBase: tools for microRNA genomics. Nucleic Acids. Res., 2008, 36, D154-158.
4. Small, E. M.; Olson, E. N. Pervasive roles of microRNAs in cardiovascular biology. Nature, 2011, 469, 336-342.
5. Nelson, P. T.; Wang, W. X.; Rajeev, B. W. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain. Pathol., 2008, 18, 130-138.
6. Pandey, A. K.; Agarwal, P.; Kaur, K.; Datta, M. MicroRNAs in diabetes: tiny players in big disease. Cell. Physiol Biochem., 2009, 23, 221-232.
7. Calin, G. A.; Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer, 2006, 6, 857-866.
8. Dong, H.; Lei, J.; Ding, L.; Wen, Y.; Ju, H.; Zhang, X. MicroRNA: Function, detection, and bioanalysis. Chem. Rev., 2013, 8, 6027-6033.
9. Tricoli, J. V.; Jacobson, J. W. MicroRNA: Potential for cancer detection, diagnosis, and prognosis. Cancer Res., 2007, 67, 4553-4555.
10. Wu, H.; Mo, Y. Y. Targeting miR-205 in breast cancer. Expert. Opin. Ther. Targets, 2009, 13, 1439-1448.
11. Lim, L. P.; Glasner, M. E.; Yekta, S.; Burge, C. B.; Bartel, D. P. Vertebrate microRNA genes. Science, 2003, 299, 1540.
12. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A. O.; Landthaler, M.; Lin, C.; Socci, N. D.; Hermida, L.; Fulci, V.; Chiaretti, S.; Foa, R.; Schliwka, J.; Fuchs, U.; Novosel, A.; Muller, R. U.; Schermer, B.; Bissels, U.; Inman, J.; Phan, Q.; Chien, M.; Weir, D. B.; Choksi, R.; De, Vita, G.; Frezzetti, D.; Trompeter, H. I.; Hornung, V.; Teng, G.; Hartmann, G.; Palkovits, M.; Di Lauro, R.; Wernet, P.; Macino, G.; Rogler, C. E.; Nagle, J. W.; Ju, J.; Papavasiliou, F. N.; Benzing, T.; Lichter, P.; Tam, W.; Brownstein, M. J.; Bosio, A.; Borkhardt, A.; Russo, J. J.; Sander, C.; Zavolan, M.; Tuschl, T. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 2007, 129, 1401-1414.
13. Wienholds, E.; Kloosterman, W. P.; Miska, E.; Alvarez-Saavedra, E.; Berezikov, E.; de Bruijn, E.; Horvitz, H. R.; Kauppinen, S.; Plasterk, R. H. MicroRNA expression in zebrafish embryonic development. Science, 2005, 309, 310-311.
14. Ason, B.; Darnell, D. K.; Wittbrodt, B.; Berezikov, E.; Kloosterman, W. P.; Wittbrodt, J.; Antin, P. B.; Plasterk, R. H. Differences in vertebrate microRNA expression. Proc. Natl. Acad. Sci. USA, 2006, 103, 14385-14389.
15. Qin, A. Y.; Zhang, X. W.; Liu, L.; Yu, J. P.; Li, H.; Wang, S. Z.; Ren, X. B.; Cao, S. MiR-205 in cancer: an angel or a devil? Eur. J. Cell, Biol., 2013, 92, 54-60.
16. Ryan, D. G.; Oliveira-Fernandes, M.; Lavker, R. M. MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. Mol Vis., 2006, 12, 1175-1184.
17. Shingara, J.; Keiger, K.; Shelton, J.; Laosinchai-Wolf, W.; Powers, P.; Conrad, R.; Brown, D.; Labourier, E. An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA, 2005, 11, 1461-1470.
18. Yu, J.; Ryan, D. G.; Getsios, S.; Oliveira-Fernandes, M.; Fatima, A.; Lavker, R. M. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc. Natl. Acad. Sci. U S A, 2008, 105, 19300-19305.
19. Yu, J.; Peng, H.; Ruan, Q, Fatima, A.; Getsios, S.; Lavker, R. M. MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2. Faseb. J., 2010, 24, 3950-3959.
20. Lin, D.; Halilovic, A.; Yue, P.; Bellner, L.; Wang, K.; Wang, L.; Zhang, C. Inhibition of miR-205 impairs the wound-healing process in human corneal epithelial cells by targeting KIR4. 1 (KCNJ10). Invest. Ophthalmol. Vis. Sci., 2013, 54, 6167-6178.
21. Mouillet, J. F.; Chu, T.; Nelson, D. M.; Mishima, T.; Sadovsky, Y. MiR-205 silences MED1 in hypoxic primary human trophoblasts. Faseb. J., 2010, 24, 2030-2039.
22. Yu, J.; Chen, Y.; Qin, L.; Cheng, L.; Ren, G.; Cong, P.; Mo, D.; He, Z. Effect of miR-205 on 3T3-L1 preadipocyte differentiation through targeting to glycogen synthase kinase 3 beta. Biotechnol. Lett., 2014 (in press).
23. Olsen, M. L.; Sontheimer, H. Functional implications for Kir4. 1 channels in glial biology: from K+ buffering to cell differentiation. J. Neurochem., 2008, 107, 589-601.
24. Marcus, D. C.; Wu, T.; Wangemann, P.; Kofuji, P. KCNJ10 (Kir4. 1) potassium channel knockout abolishes endocochlear potential. Am. J. Physiol Cell. Physiol, 2002, 282, C403-407.
25. Li, C.; Finkelstein, D.; Sherr, C. J. Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proc. Natl. Acad. Sci. USA, 2013, 110, E1112-1121.
26. Greene, S. B.; Gunaratne, P. H.; Hammond, S. M.; Rosen, J. M. A putative role for microRNA-205 in mammary epithelial cell progenitors. J. Cell. Sci., 2010, 123, 606-618.
27. Wang, D.; Zhang, Z.; O'Loughlin, E.; Wang, L.; Fan, X.; Lai, E. C.; Yi, R. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI(3)K pathway. Nat. Cell. Biol., 2013, 15, 1153-1163.
28. Bezler, M.; Hengstler, J. G.; Ullrich, A. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. Mol. Oncol., 2012, 6, 516-529.
29. Sempere, L. F.; Christensen, M.; Silahtaroglu, A.; Bak, M.; Heath, C. V.; Schwartz, G.; Wells, W.; Kauppinen, S.; Cole, C. N. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res., 2007, 67, 11612-11620.
30. Gregory, P. A.; Bert, A. G.; Paterson, E. L.; Barry, S. C.; Tsykin, A.; Farshid, G.; Vadas, M. A.; Khew-Goodall, Y.; Goodall, G. J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol., 2008, 10, 593-601.
31. Baffa, R.; Fassan, M.; Volinia, S.; O'Hara, B.; Liu, C. G.; Palazzo, J. P.; Gardiman, M.; Rugge, M.; Gomella, L. G.; Croce, C. M.; Rosenberg, A. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol., 2009, 219, 214-221.
32. Iorio, M. V.; Casalini, P.; Piovan, C.; Di Leva, G.; Merlo, A.; Triulzi, T.; Menard, S.; Croce, C. M.; Tagliabue, E. microRNA-205 regulates HER3 in human breast cancer. Cancer Res., 2009, 69, 2195-2200.
33. Wang, Z.; Liao, H.; Deng, Z.; Yang, P.; Du, N.; Zhanng, Y.; Ren, H. miRNA-205 affects infiltration and metastasis of breast cancer. Biochem. Biophys. Res. Commun., 2013, 441, 139-143.
34. Wu, H.; Zhu, S.; Mo, Y. Y. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res., 2009, 19, 439-448.
35. Adachi, R.; Horiuchi, S.; Sakurazawa, Y.; Hasegawa, T.; Sato, K.; Sakamaki, T. ErbB2 down-regulates microRNA-205 in breast cancer. Biochem. Biophys. Res. Commun., 2011, 411, 804-808.
36. Piovan, C.; Palmieri, D.; Di Leva, G.; Braccioli, L.; Casalini, P.; Nuovo, G.; Tortoreto, M.; Sasso, M.; Plantamura, I.; Triulzi, T.; Taccioli, C.; Tagliabue, E.; Iorio, M. V.; Croce, C. M. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol., 2012, 6, 458-472.
37. Mahamodhossen Y. A.; Liu W.; Rong-Rong Z. Triple-negative breast cancer: new perspectives for novel therapies. Med. Oncol., 2013, 30, 653.
38. Quesne J. L.; Jones J.; Warren J.; Dawson S. J.; Ali H. R.; Bardwell G.; Blows F.; Pharoah P.; Caldas C. Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J. Pathol., 2012, 227, 306-314.
39. Weigelt B.; Geyer F. C.; Natrajan R.; Lopez-Garcia M. A.; Ahmad A. S.; Savage K.; Kreike B.; Reis-Filho J. S. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J. Pathol., 2010, 220, 45-57.
40. Savad S.; Mehdipour P.; Miryounesi M.; Shirkoohi R.; Fereidooni F.; Mansouri F.; Modarressi M. H. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian. Pac. J. Cancer Prev., 2012, 13, 873-877.
41. Radojicic J.; Zaravinos A.; Vrekoussis T.; Kafousi M.; Spandidos DA.; Stathopoulos EN. MicroRNA expression analysis in triplenegative (ER, PR and Her2/neu) breast cancer. Cell. Cycle, 2011, 10, 507-517.
42. Liu J.; Mao Q.; Liu Y.; Hao X.; Zhang S.; Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin. J. Cancer Res., 2013, 25, 46-54.
43. Wang S.; Huang J.; Lyu H.; Lee C. K.; Tan J.; Wang J.; Liu B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell. Death Dis., 2013, 4, e556.
44. Porkka, K. P.; Pfeiffer, M. J.; Waltering, K. K.; Vessella, R. L.; Tammela, T. L.; Visakorpi, T. MicroRNA expression profiling in prostate cancer. Cancer Res., 2007, 67, 6130-6135.
45. Gandellini, P.; Folini, M.; Longoni, N.; Pennati, M.; Binda, M.; Colecchia, M.; Salvioni, R.; Supino, R.; Moretti, R.; Limonta, P.; Valdagni, R.; Daidone, M. G.; Zaffaroni, N. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res., 2009, 69, 2287-2295.
46. Majid, S.; Dar, A. A.; Saini, S.; Yamamura, S.; Hirata, H.; Tanaka, Y.; Deng, G.; Dahiya, R. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer, 2010, 116, 5637-5649.
47. Bhatnagar, N.; Li, X.; Padi, S. K.; Zhang, Q.; Tang, M. S.; Guo, B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis., 2010, 1, e105.
48. Watahiki, A.; Wang, Y.; Morris, J.; Dennis, K.; O'Dwyer, H. M.; Gleave, M.; Gout, P. W.; Wang, Y. MicroRNAs associated with metastatic prostate cancer. PLoS One, 2011, 6, e24950.
49. Gandellini, P.; Profumo, V.; Casamichele, A.; Fenderico, N.; Borrelli, S.; Petrovich, G.; Santilli, G.; Callari, M.; Colecchia, M.; Pozzi, S.; De Cesare, M.; Folini, M.; Valdagni, R.; Mantovani, R.; Zaffaroni, N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell. Death Differ., 2012, 19, 1750-1760.
50. Signoretti, S.; Loda, M. Defining cell lineages in the prostate epithelium. Cell Cycle, 2006, 5, 138-141.
51. Signoretti, S.; Pires, M. M.; Lindauer, M.; Horner, J. W.; Grisanzio, C.; Dhar, S.; Majumder, P.; McKeon, F.; Kantoff, P. W.; Sellers, W. R.; Loda, M. p63 regulates commitment to the prostate cell lineage. Proc. Natl. Acad. Sci. USA, 2005, 102, 11355-11360.
52. Koster, MI.; Dai, D.; Marinari, B.; Sano, Y.; Costanzo, A.; Karin, M.; Roop, DR. p63 induces key target genes required for epidermal morphogenesis. Proc. Natl. Acad. Sci. USA, 2007, 104, 3255-3260.
53. Tucci, P.; Agostini, M.; Grespi, F.; Markert, E. K.; Terrinoni, A.; Vousden, K. H.; Muller, P. A.; Dotsch, V.; Kehrloesser, S.; Sayan, B. S.; Giaccone, G.; Lowe, S. W.; Takahashi, N.; Vandenabeele, P.; Knight, R. A.; Levine, A. J.; Melino, G. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA, 2012, 109, 15312-15317.
54. Puhr, M.; Hoefer, J.; Schafer, G.; Erb, H. H.; Oh, S. J.; Klocker, H.; Heidegger, I.; Neuwirt, H.; Culig, Z. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol., 2012, 181, 2188-2201.
55. Hulf, T.; Sibbritt, T.; Wiklund, E. D.; Bert, S.; Strbenac, D.; Statham, A. L.; Robinson, MD.; Clark, S. J. Discovery pipeline for epigenetically deregulated miRNAs in cancer: integration of primary miRNA transcription. BMC Genomics, 2011, 12, 54.
56. Ke, X. S.; Qu, Y.; Rostad, K.; Li, W. C.; Lin, B.; Halvorsen, O. J.; Haukaas, S. A.; Jonassen, I.; Petersen, K.; Goldfinger, N.; Rotter, V.; Akslen, L. A.; Oyan, A. M.; Kalland, K. H. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One, 2009, 4, e4687.
57. Hulf, T.; Sibbritt, T.; Wiklund, ED.; Patterson, K.; Song, J. Z.; Stirzaker, C.; Qu, W.; Nair, S.; Horvath, L. G.; Armstrong, N. J.; Kench, J. G.; Sutherland, R. L.; Clark, S. J. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene, 2013, 32, 2891-2899.
58. Wang, Q.; Carroll, J. S.; Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell., 2005, 19, 631-642.
59. Verdoodt, B.; Neid, M.; Vogt, M.; Kuhn, V.; Liffers, S. T.; Palisaar, R. J.; Noldus, J.; Tannapfel, A.; Mirmohammadsadegh A. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. Int. J. Oncol., 2013, 43, 307-314.
60. Hagman, Z.; Haflidadottir, B. S.; Ceder, J. A.; Larne, O.; Bjartell, A.; Lilja, H.; Edsjo, A.; Ceder, Y. miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br. J. Cancer, 2013, 108, 1668-1676.
61. Szczyrba, J.; Nolte, E.; Hart, M.; Doll, C.; Wach, S.; Taubert, H.; Keck, B.; Kremmer, E.; Stohr, R.; Hartmann, A.; Wieland, W.; Wullich, B.; Grasser, F. A. Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma. Int. J. Cancer, 2013, 132, 775-784.
62. Barboro, P.; Repaci, E.; Rubagotti, A.; Salvi, S.; Boccardo, S.; Spina, B.; Truini, M.; Introini, C.; Puppo, P.; Ferrari, N.; Carmignani, G.; Boccardo, F.; Balbi, C. Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br. J. Cancer, 2009, 100, 1608-1616.
63. Szczyrba, J; Loprich, E.; Wach, S.; Jung, V.; Unteregger, G.; Barth, S.; Grobholz, R.; Wieland, W.; Stohr, R.; Hartmann, A.; Wullich, B.; Grasser, F. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol. Cancer Res., 2010, 8, 529-538.
64. Schaefer, A.; Jung, M.; Mollenkopf, H. J.; Wagner, I.; Stephan, C.; Jentzmik, F.; Miller, K.; Lein, M.; Kristiansen, G.; Jung, K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer, 2010, 126, 1166-11676.
65. Gandellini, P.; Giannoni, E.; Casamichele, A.; Taddei, M. L.; Callari, M.; Piovan, C.; Valdagni, R.; Pierotti, M. A.; Zaffaroni, N.; Chiarugi, P. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid. Redox. Signal., 2013, 20, 1045-1059.
66. Wang, N.; Li, Q.; Feng, N. H.; Cheng, G.; Guan, Z. L.; Wang, Y.; Qin, C.; Yin, C. J.; Hua, L. X. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian. J. Androl., 2013, 15, 735-741.
67. Summy, J. M.; Gallick, G. E. Src family kinases in tumor progression and metastasis. Cancer Metastasis. Rev., 2003, 22, 337-358.
68. Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Dev. Biol., 1997, 13, 513-609.
69. Kalogirou, C.; Spahn, M.; Krebs, M.; Joniau, S.; Lerut, E.; Burger, M.; Scholz, C. J.; Kneitz, S.; Riedmiller, H.; Kneitz, B. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int. J. Mol. Sci., 2013, 14, 21414-21434.
70. Srivastava, A.; Goldberger, H.; Dimtchev, A.; Ramalinga, M.; Chijioke, J.; Marian, C.; Oermann, E. K.; Uhm, S.; Kim, J. S.; Chen, L. N.; Li, X.; Berry, D. L.; Kallakury, B. V.; Chauhan, S. C.; Collins, S. P.; Suy, S.; Kumar, D. MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205 and miR-214. PLoS One, 2013, 8, e76994.
71. Ngalame, N. N.; Tokar, E. J.; Person, R. J.; Xu, Y.; Waalkes, M. P. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol. Sci., 2014, 138, 268-277.
72. Huang, W.; Jin, Y.; Yuan, Y.; Bai, C.; Wu, Y.; Zhu, H.; Lu, S. Validation and target gene screening of hsa-miR-205 in lung squamous cell carcinoma. Chin. Med. J., 2014, 127, 272-278.
73. Markou, A.; Tsaroucha, E. G.; Kaklamanis, L.; Fotinou, M.; Georgoulias, V.; Lianidou, E. S. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem., 2008, 54, 1696-1704.
74. Yanaihara, N.; Caplen, N.; Bowman, E.; Seike, M.; Kumamoto, K.; Yi, M.; Stephens, R. M.; Okamoto, A.; Yokota, J.; Tanaka, T.; Calin, G. A.; Liu, C. G.; Croce, C. M.; Harris, C. C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 2006, 9, 189-198.
75. Lebanony, D.; Benjamin, H.; Gilad, S.; Ezagouri, M.; Dov, A.; Ashkenazi, K.; Gefen, N.; Izraeli, S.; Rechavi, G.; Pass, H.; Nonaka, D.; Li, J.; Spector, Y.; Rosenfeld, N.; Chajut, A.; Cohen, D.; Aharonov, R.; Mansukhani, M. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol., 2009, 27, 2030-2037.
76. Hamamoto, J.; Soejima, K.; Yoda, S.; Naoki, K.; Nakayama, S.; Satomi, R.; Terai, H.; Ikemura, S.; Sato, T.; Yasuda, H.; Hayashi, Y.; Sakamoto, M.; Takebayashi, T.; Betsuyaku, T. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Mol. Med. Rep., 2013, 8, 456-462.
77. Bishop, J. A.; Benjamin, H.; Cholakh, H.; Chajut, A.; Clark, D. P.; Westra, W. H. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin. Cancer Res., 2010, 16, 610-619.
78. Lu, Y.; Govindan, R.; Wang, L.; Liu, P. Y.; Goodgame, B.; Wen, W.; Sezhiyan, A.; Pfeifer, J.; Li, Y. F.; Hua, X.; Wang, Y.; Yang, P.; You, M. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis, 2012, 33, 1046-1054.
79. Del Vescovo, V.; Cantaloni, C.; Cucino, A.; Girlando, S.; Silvestri, M.; Bragantini, E.; Fasanella, S.; Cuorvo, LV.; Palma, P. D.; Rossi, G.; Papotti, M.; Pelosi, G.; Graziano, P.; Cavazza, A.; Denti, M. A.; Barbareschi, M. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am. J. Surg. Pathol., 2011, 35, 268-275.
80. Huang, W.; Hu, J.; Yang, D. W.; Fan, X. T.; Jin, Y.; Hou, Y. Y.; Wang, J. P.; Yuan, Y. F.; Tan, Y. S.; Zhu, X. Z.; Bai, C. X.; Wu, Y.; Zhu, H. G.; Lu, S. H. Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens. Am. J. Respir. Crit. Care. Med., 2012, 186, 1160-1167.
81. Cai, J.; Fang, L.; Huang, Y.; Li, R.; Yuan, J.; Yang, Y.; Zhu, X.; Chen, B.; Wu, J.; Li, M. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in nonsmall cell lung cancer. Cancer Res., 2013, 73, 5402-5415.
82. Jiang, M.; Zhang, P.; Hu, G.; Xiao, Z.; Xu, F.; Zhong, T.; Huang, F.; Kuang, H.; Zhang, W. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol. Cell. Biochem., 2013, 383, 67-75.
83. Aushev, V. N.; Zborovskaya, I. B.; Laktionov, K. K.; Girard, N.; Cros, M. P.; Herceg, Z.; Krutovskikh, V. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One, 2013, 8, e78649.
84. Song, H.; Bu, G. MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. Biochem. Biophys. Res. Commun., 2009, 388, 400-405.
85. Li, Y.; Lu, W.; Bu, G. Essential role of the low density lipoprotein receptor-related protein in vascular smooth muscle cell migration. FEBS. Lett., 2003, 555, 346-350.
86. Larzabal, L.; de Aberasturi, A. L.; Redrado, M.; Rueda, P.; Rodriguez, M. J.; Bodegas, M. E.; Montuenga, L. M.; Calvo, A. TMPRSS4 regulates levels of integrin alpha5 in NSCLC through miR-205 activity to promote metastasis. Br. J. Cancer, 2014, 110, 764-774.
87. Tellez, C. S.; Juri, D. E.; Do, K.; Bernauer, A. M.; Thomas, C. L.; Damiani, L. A.; Tessema, M.; Leng, S.; Belinsky, S. A. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res., 2011, 71, 3087-3097.
88. Dar, A. A.; Majid, S.; de Semir, D.; Nosrati, M.; Bezrookove, V.; Kashani-Sabet, M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol Chem., 2011, 286, 16606-16614.
89. Alla, V.; Kowtharapu, B. S.; Engelmann, D.; Emmrich, S.; Schmitz, U.; Steder, M.; Putzer, B. M. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle, 2012, 11, 3067-3078.
90. Noguchi, S.; Iwasaki, J.; Kumazaki, M.; Mori, T.; Maruo, K.; Sakai, H.; Yamada, N.; Shimada, K.; Naoe, T.; Kitade, Y.; Akao, Y. Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. Mol. Ther., 2013, 21, 1204-1211.
91. Noguchi, S.; Mori, T.; Hoshino, Y.; Yamada, N.; Maruo, K.; Akao, Y. MicroRNAs as tumour suppressors in canine and human melanoma cells and as a prognostic factor in canine melanomas. Vet. Comp. Oncol, 2013, 11, 113-123.
92. Liu, S.; Tetzlaff, M. T.; Liu, A.; Liegl-Atzwanger, B.; Guo, J.; Xu, X. Loss of microRNA-205 expression is associated with melanoma progression. Lab. Invest., 2012, 92, 1084-1096.
93. Hanna, J. A.; Hahn, L.; Agarwal, S.; Rimm, D. L. In situ measurement of miR-205 in malignant melanoma tissue supports its role as a tumor suppressor microRNA. Lab. Invest., 2012, 92, 1390-1397.
94. Kozubek, J.; Ma, Z.; Fleming, E.; Duggan, T.; Wu, R.; Shin, D. G.; Dadras, S. S. In-depth characterization of microRNA transcriptome in melanoma. PLoS One, 2013, 8, e72699.
95. Dahmke, I. N.; Backes, C.; Rudzitis-Auth, J.; Laschke, M. W.; Leidinger, P.; Menger, M. D.; Meese, E.; Mahlknecht, U. Curcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly altered. PLoS One, 2013, 8, e81122.
96. Gottardo, F.; Liu, C. G.; Ferracin, M.; Calin, G. A.; Fassan, M.; Bassi, P.; Sevignani, C.; Byrne, D.; Negrini, M.; Pagano, F.; Gomella, L. G.; Croce, C. M.; Baffa, R. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol., 2007, 25, 387-392.
97. Wiklund, E. D.; Bramsen, J. B.; Hulf, T.; Dyrskjot, L.; Ramanathan, R.; Hansen, T. B.; Villadsen, S. B.; Gao, S.; Ostenfeld, M. S.; Borre, M.; Peter, M. E.; Orntoft, T. F.; Kjems, J.; Clark, S. J. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer, 2011, 128, 1327-1334.
98. Tran, M. N.; Choi, W.; Wszolek, M. F.; Navai, N.; Lee, I. L.; Nitti, G.; Wen, S.; Flores, E. R.; Siefker-Radtke, A.; Czerniak, B.; Dinney, C.; Barton, M.; McConkey, D. J. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J. Biol. Chem., 2013, 288, 3275-3288.
99. Dip, N.; Reis, S. T.; Timoszczuk, L. S.; Viana, N. I.; Piantino, C. B.; Morais, D. R.; Moura, C. M.; Abe, D. K.; Silva, I. A.; Srougi, M.; Dall'Oglio, M. F.; Leite, K. R. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J. Urol, 2012, 188, 1951-1956.
100. Lee, H.; Jun, S. Y.; Lee, Y. S.; Lee, H. J.; Lee, W. S.; Park, C. S. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows. Arch., 2013, 464, 213-220.
101. Tran, N.; McLean, T.; Zhang, X.; Zhao, C. J.; Thomson, J. M.; O'Brien, C.; Rose, B. MicroRNA expression profiles in head and neck cancer cell lines. Biochem. Biophys. Res. Commun., 2007, 358, 12-17.
102. Fletcher, A. M.; Heaford, A. C.; Trask, D. K. Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. Transl. Oncol., 2008, 1, 202-208.
103. Childs, G.; Fazzari, M.; Kung, G.; Kawachi, N.; Brandwein-Gensler, M.; McLemore, M.; Chen, Q.; Burk, R. D.; Smith, R. V.; Prystowsky, M. B.; Belbin, T. J.; Schlecht, N. F. Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am. J. Pathol., 2009, 174, 736-745.
104. Zidar, N.; Bostjancic, E.; Gale, N.; Kojc, N.; Poljak, M.; Glavac, D.; Cardesa, A. Down-regulation of microRNAs of the miR-200 family and miR-205, and an altered expression of classic and desmosomal cadherins in spindle cell carcinoma of the head and neck--hallmark of epithelial-mesenchymal transition. Hum. Pathol., 2011, 42, 482-488.
105. Qu, C.; Liang, Z.; Huang, J.; Zhao, R.; Su, C.; Wang, S.; Wang, X.; Zhang, R.; Lee, M. H.; Yang, H. MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle, 2012, 11, 785-796.
106. Wang, D.; Wang, S.; Liu, Q.; Wang, M.; Wang, C.; Yang, H. SZ-685C exhibits potent anticancer activity in both radiosensitive and radioresistant NPC cells through the miR-205-PTEN-Akt pathway. Oncol. Rep., 2013, 29, 2341-2347.
107. Kim, J. S.; Yu, S. K.; Lee, M. H.; Park, M. G.; Park, E.; Kim, S. G.; Lee, S. Y.; Kim, C. S.; Kim, H. J.; Chun, H. S.; Chun, S. W.; Kim do, K. MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Mol. Cells, 2013, 35, 17-24.
108. Kim, J. S.; Park, S. Y.; Lee, S. A.; Park, M. G.; Yu, S. K.; Lee, M. H.; Park, M. R.; Kim, S. G.; Oh, J. S.; Lee, S. Y.; Kim, C. S.; Kim, H. J.; Chun, H. S.; Kim, J. S.; Moon, S. M.; Kim do, K. MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Mol. Cell. Biochem., 2014, 387, 71-79.
109. Cao, P.; Zhou, L.; Zhang, J.; Zheng, F.; Wang, H.; Ma, D.; Tian, J. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck, 2013, 35, 720-728.
110. Tian, L.; Zhang, J.; Ge, J.; Xiao, H.; Lu, J.; Fu, S.; Liu, M.; Sun, Y. MicroRNA-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma. Med. Oncol., 2014, 31, 785.
111. Goto, Y.; Yue, L.; Yokoi, A.; Nishimura, R.; Uehara, T.; Koizumi, S.; Saikawa, Y. A novel single-nucleotide polymorphism in the 3'-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res., 2001, 7, 1952-1956.
112. Moldovan, G. L.; Pfander, B.; Jentsch, S. PCNA, the maestro of the replication fork. Cell., 2007, 129, 665-679.
113. Feber, A.; Xi, L.; Luketich, JD.; Pennathur, A.; Landreneau, R. J.; Wu, M.; Swanson, S. J.; Godfrey, T. E.; Litle, V. R. MicroRNA expression profiles of esophageal cancer. J. Thorac. Cardiovasc. Surg., 2008, 135, 255-260.
114. Kimura, S.; Naganuma, S.; Susuki, D.; Hirono, Y.; Yamaguchi, A.; Fujieda, S.; Sano, K.; Itoh H. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol. Rep., 2010, 23, 1625-1633.
115. Dijckmeester, W. A.; Wijnhoven, B. P.; Watson, D. I.; Leong, M. P.; Michael, M. Z.; Mayne, G. C.; Bright, T.; Astill, D.; Hussey, D. J. MicroRNA-143 and-205 expression in neosquamous esophageal epithelium following Argon plasma ablation of Barrett's esophagus. J. Gastrointest. Surg., 2009, 13, 846-853.
116. Yang, H.; Gu, J.; Wang, K. K.; Zhang, W.; Xing, J.; Chen, Z.; Ajani, J. A.; Wu, X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res., 2009, 15, 5744-5752.
117. Wijnhoven, B. P.; Hussey, D. J.; Watson, D. I.; Tsykin, A.; Smith, C. M.; Michael, M. Z. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br. J. Surg., 2010, 97, 853-861.
118. Wu, X.; Ajani, J. A.; Gu, J.; Chang, D. W.; Tan, W.; Hildebrandt, M. A.; Huang, M.; Wang, K. K.; Hawk, E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev. Res. (Phila)., 2013, 6, 196-205.
119. Matsushima, K.; Isomoto, H.; Kohno, S.; Nakao, K. MicroRNAs and esophageal squamous cell carcinoma. Digestion, 2010, 82, 138-144.
120. Matsushima, K.; Isomoto, H.; Yamaguchi, N.; Inoue, N.; Machida, H.; Nakayama, T.; Hayashi, T.; Kunizaki, M.; Hidaka, S.; Nagayasu, T.; Nakashima, M.; Ujifuku, K.; Mitsutake, N.; Ohtsuru, A.; Yamashita, S.; Korpal, M.; Kang, Y.; Gregory, P. A.; Goodall, G. J.; Kohno, S.; Nakao, K. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J. Transl. Med., 2011, 9, 30.
121. Fassan, M.; Volinia, S.; Palatini, J.; Pizzi, M.; Baffa, R.; De Bernard, M.; Battaglia, G.; Parente, P.; Croce, C. M.; Zaninotto, G.; Ancona, E.; Rugge, M. MicroRNA expression profiling in human Barrett's carcinogenesis. Int. J. Cancer, 2011, 129, 1661-1670.
122. Saad, R.; Chen, Z.; Zhu, S.; Jia, P.; Zhao, Z.; Washington, M. K.; Belkhiri, A.; El-Rifai, W. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One, 2013, 8, e64463.
123. Akagi, I.; Miyashita, M.; Ishibashi, O.; Mishima, T.; Kikuchi, K.; Makino, H.; Nomura, T.; Hagiwara, N.; Uchida, E.; Takizawa, T. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis. Esophagus., 2011, 24, 523-530.
124. Zhao, B. S.; Liu, S. G.; Wang, T. Y.; Ji, Y. H.; Qi, B.; Tao, Y. P.; Li, H. C.; Wu, X. N. Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. Asian Pac. J. Cancer Prev., 2013, 14, 139-143.
125. Iorio, M. V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C. G.; Alder, H.; Calin, G. A.; Menard, S.; Croce, C. M. MicroRNA signatures in human ovarian cancer. Cancer Res., 2007, 67, 8699-8707.
126. Gadducci, A.; Sergiampietri, C.; Lanfredini, N.; Guiggi, I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol., 2014, 30, 266-271.
127. Chen, J.; Wang, L.; Matyunina, LV.; Hill, C. G.; McDonald, J. F. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol. Oncol., 2011, 121, 200-205.
128. Nam, E. J.; Lee, M.; Yim, G. W.; Kim, J. H.; Kim, S.; Kim, S. W.; Kim, Y. T. MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line. BMC Med. Genomics, 2012, 5, 18.
129. Zheng, H.; Zhang, L.; Zhao, Y.; Yang, D.; Song, F.; Wen, Y.; Hao, Q.; Hu, Z, Zhang, W.; Chen, K. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One, 2013, 8, e77853.
130. Wu, W.; Lin, Z.; Zhuang, Z.; Liang, X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur. J. Cancer Prev., 2009, 18, 50-55.
131. Chung, T. K.; Cheung, T. H.; Huen, N. Y.; Wong, K. W.; Lo, K. W.; Yim, S. F.; Siu, N. S.; Wong, Y. M.; Tsang, P. T.; Pang, M. W.; Yu, M. Y.; To, K. F.; Mok, S. C.; Wang, V. W.; Li, C.; Cheung, A. Y.; Doran, G.; Birrer, M. J.; Smith, D. I.; Wong, Y. F. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int. J. Cancer, 2009, 124, 1358-1365.
132. Hiroki, E.; Akahira, J.; Suzuki, F.; Nagase, S.; Ito, K.; Suzuki, T.; Sasano, H.; Yaegashi, N. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci., 2010, 101, 241-249.
133. Lee, T. S.; Jeon, H. W.; Kim, Y. B.; Kim, Y. A.; Kim, M. A.; Kang, S. B. Aberrant microRNA expression in endometrial carcinoma using formalin-fixed paraffin-embedded (FFPE) tissues. PLoS One, 2013, 8, e81421.
134. Karaayvaz, M.; Zhang, C.; Liang, S.; Shroyer, K. R.; Ju, J. Prognostic significance of miR-205 in endometrial cancer. PLoS One, 2012, 7, e35158.
135. Su, N.; Qiu, H.; Chen, Y.; Yang, T.; Yan, Q.; Wan, X. miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol. Rep., 2013, 29, 2297-2302.
136. Xie, H.; Zhao, Y.; Caramuta, S.; Larsson, C.; Lui, WO. miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS One, 2012, 7, e46990.
137. McKenna, D. J.; Patel, D.; McCance, D. J. miR-24 and miR-205 expression is dependent on HPV onco-protein expression in keratinocytes. Virology, 2014, 448, 210-216.
138. Dou, L.; Zheng, D.; Li, J.; Li, Y.; Gao, L.; Wang, L.; Yu, L. Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression. Oncogene, 2012, 31, 507-517.
139. Dou, L.; Li, J.; Zheng, D.; Li, Y.; Gao, X.; Xu, C.; Gao, L.; Wang, L.; Yu, L. MicroRNA-205 downregulates mixed-lineage-AF4 oncogene expression in acute lymphoblastic leukemia. Onco. Targets. Ther., 2013, 6, 1153-1160.
140. Yue, X.; Wang, P.; Xu, J.; Zhu, Y.; Sun, G.; Pang, Q.; Tao, R. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol. Rep., 2012, 27, 1200-1206.
141. Hou, S. X.; Ding, B. J.; Li, H. Z.; Wang, L.; Xia, F.; Du, F.; Liu, L. J.; Liu, Y. H.; Liu, X. D.; Jia, J. F.; Li, L.; Wu, Z. L.; Zhao, G.; Zhang, Z. G.; Deng, Y. C. Identification of microRNA-205 as a potential prognostic indicator for human glioma. J. Clin. Neurosci., 2013, 20, 933-937.
142. Majid, S.; Saini, S.; Dar, A. A.; Hirata, H.; Shahryari, V.; Tanaka, Y.; Yamamura, S.; Ueno, K.; Zaman, M. S.; Singh, K.; Chang, I.; Deng, G.; Dahiya, R. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res., 2011, 71, 2611-2621.
143. Wang, X. Y.; Wu, M. H.; Liu, F.; Li, Y.; Li, N.; Li, G. Y.; Shen, S. R. Differential miRNA expression and their target genes between NGX6-positive and negative colon cancer cells. Mol. Cell. Biochem., 2010, 345, 283-290.
144. Zhang, T.; Zhang, J.; Cui, M.; Liu, F.; You, X.; Du, Y.; Gao, Y.; Zhang, S.; Lu, Z.; Ye, L.; Zhang, X. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia, 2013, 15, 1282-1291.
145. Cui, M.; Wang, Y.; Sun, B.; Xiao, Z.; Ye, L.; Zhang, X. MiR-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-CoA synthetase long-chain family member 1 (ACSL1) mRNA. Biochem. Biophys. Res. Commun., 2014, 444, 270-275.
146. Cui, M.; Xiao, Z.; Sun, B.; Wang, Y.; Zheng, M.; Ye, L.; Zhang, X. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4. Biochem. Biophys. Res. Commun., 2014, 445, 651-655.
147. Okamoto, K.; Miyoshi, K.; Murawaki, Y. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One, 2013, 8, e77623.
148. Singh, S.; Chitkara, D.; Kumar, V.; Behrman, S. W.; Mahato, RI. miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Lett., 2013, 334, 211-220.
149. Kajihara, I.; Jinnin, M.; Harada, M.; Makino, K.; Honda, N.; Makino, T.; Igata, T.; Masuguchi, S.; Fukushima, S.; Ihn, H. miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation. Arch. Dermatol. Res., 2014, 4, 367-374.